Six-Minute Walk Is a Better Outcome Measure Than Treadmill Walking Tests in Therapeutic Trials of Patients With Peripheral Artery Disease
Year: 2014
Type: article
Abstract: L ower-extremity peripheral artery disease (PAD) affects 8 million people in the United States and >200 million men and women worldwide. 1,2PAD will become increasingly common as the US population survives longer with chronic disease.Although intermittent claudication is the most frequent classic symptom of PAD, many patients with PAD are asymptomatic or have exertional leg symptoms other than intermittent claudication. 3,4Patients with PAD have slower walking speed, poorer walking endurance, and substantially lower physical activity levels compared with people without PAD. 3,5][14] Therefore, an important treatment goal in patients with PAD is improving walking performance and preventing mobility loss. Response by Hiatt et al p 68Despite the functional limitations present in PAD, few medical therapies exist for improving walking performance and preventing mobility loss in patients with PAD.6][17] Of these 2 medications, pentoxifylline is not substantially better than placebo. 15,17ilostazol provides only modest improvement in treadmill walking performance. 16,17Although supervised treadmill exercise significantly improves walking performance in patients with PAD, 18,19 medical insurance typically does not pay for costs of supervised exercise for patients with PAD.Thus, most patients with PAD do not participate in supervised treadmill exercise. 20
Source: Circulation
Language: English
Subfield: Surgery
Field: Medicine
Domain: Health Sciences
Open Access status: bronze
OpenAlex ID: W2071793001